Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Real world data in rheumatology.

Hyrich KL.

Semin Arthritis Rheum. 2019 Dec;49(3S):S22-S24. doi: 10.1016/j.semarthrit.2019.09.021.

PMID:
31779845
2.

Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as 'satisfactory'.

Gwinnutt JM, Hyrich KL; RAMS Co-Investigators , Lunt M, Barton A, Verstappen SMM.

Rheumatology (Oxford). 2019 Nov 15. pii: kez497. doi: 10.1093/rheumatology/kez497. [Epub ahead of print]

PMID:
31729526
3.

Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Chadwick L, Kearsley-Fleet L, Brown N; BSRBR-RA Control Centre Consortium; BSRBR-RA Contributors Group, Watson KD, Lunt M, Symmons DPM, Hyrich KL.

Rheumatology (Oxford). 2019 Aug 5. pii: kez277. doi: 10.1093/rheumatology/kez277. [Epub ahead of print]

PMID:
31722431
4.

The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.

Davies R, Cock D, Kearsley-Fleet L, Southwood T, Baildam E, Beresford MW, Foster HE, Thomson W, Ramanan A, Hyrich KL; British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN) and the Biologics for Children with Rheumatic Diseases (BCRD) study.

Rheumatology (Oxford). 2019 Oct 12. pii: kez449. doi: 10.1093/rheumatology/kez449. [Epub ahead of print]

PMID:
31605484
5.

Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis.

Nair N, Plant D, Verstappen SM, Isaacs JD, Morgan AW, Hyrich KL, Barton A, Wilson AG.

Rheumatology (Oxford). 2019 Oct 10. pii: kez411. doi: 10.1093/rheumatology/kez411. [Epub ahead of print]

6.

A UK study: vocational experiences of young adults with juvenile idiopathic arthritis.

Lunt LE, Bosworth A, Bezzant M, Walker-Bone K, Hyrich KL, Thomson W, McDonagh JE, Verstappen SMM.

Pediatr Rheumatol Online J. 2019 Aug 6;17(1):54. doi: 10.1186/s12969-019-0357-y. No abstract available.

7.

Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions.

Shoop-Worrall SJW, Wu Q, Davies R, Hyrich KL, Wedderburn LR.

Lancet Child Adolesc Health. 2019 Oct;3(10):725-733. doi: 10.1016/S2352-4642(19)30188-9. Epub 2019 Jul 19. Review.

PMID:
31331873
8.

The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate.

Hope HF, Hyrich KL, Anderson J, Bluett J, Sergeant JC, Barton A, Cordingley L, Verstappen SMM; RAMS co-investigators .

Rheumatology (Oxford). 2019 Jul 13. pii: kez274. doi: 10.1093/rheumatology/kez274. [Epub ahead of print]

PMID:
31302692
9.

Predicting Remission Remains a Challenge in Patients with Juvenile Idiopathic Arthritis.

Shoop-Worrall SJW, Hyrich KL.

J Rheumatol. 2019 Jun;46(6):552-554. doi: 10.3899/jrheum.181245. No abstract available.

PMID:
31154444
10.

Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.

Pan Y, Norton S, Gwinnutt JM, Kearsley-Fleet L, Symmons DPM, Lunt M, Young A; BSRBR-RA Control Centre Consortium, Hyrich KL, Verstappen SMM.

PLoS One. 2019 May 20;14(5):e0215999. doi: 10.1371/journal.pone.0215999. eCollection 2019.

11.

Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, Norton S, Cope AP, Hyrich KL, Galloway JB.

Rheumatology (Oxford). 2019 Oct 1;58(10):1767-1776. doi: 10.1093/rheumatology/kez037.

PMID:
30982886
12.

Comparing Proxy, Adolescent and Adult Assessments of Functional Ability in Adolescents with Juvenile Idiopathic Arthritis.

Shoop-Worrall SJ, Hyrich KL, Verstappen SM, Sergeant JC, Baildam E, Chieng A, Davidson J, Foster H, Ioannou Y, McErlane F, Wedderburn LR, Thomson W, McDonagh JE.

Arthritis Care Res (Hoboken). 2019 Mar 15. doi: 10.1002/acr.23877. [Epub ahead of print]

PMID:
30875458
13.

Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis.

Kearsley-Fleet L, Vicente González L, Steinke D, Davies R, De Cock D, Baildam E, Beresford MW, Foster HE, Southwood TR, Thomson W, Hyrich KL; Biologics for Children with Rheumatic Diseases (BCRD) Study and the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN).

Rheumatology (Oxford). 2019 Mar 8. pii: kez048. doi: 10.1093/rheumatology/kez048. [Epub ahead of print]

14.

Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.

Kearsley-Fleet L, Sampath S, McCann LJ, Baildam E, Beresford MW, Davies R, De Cock D, Foster HE, Southwood TR, Thomson W, Hyrich KL.

Rheumatology (Oxford). 2019 Feb 1;58(2):331-335. doi: 10.1093/rheumatology/key306.

15.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
16.

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.

Kearsley-Fleet L, Beresford MW, Davies R, De Cock D, Baildam E, Foster HE, Southwood TR, Thomson W, Hyrich KL.

Rheumatology (Oxford). 2019 Jan 1;58(1):94-102. doi: 10.1093/rheumatology/key262.

17.

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.

Fagerli KM, Kearsley-Fleet L, Mercer LK, Watson K, Packham J, Symmons DPM, Hyrich KL.

Rheumatology (Oxford). 2019 Jan 1;58(1):80-85. doi: 10.1093/rheumatology/key241.

18.

Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).

Sergeant JC, Hyrich KL, Anderson J, Kopec-Harding K, Hope HF, Symmons DPM; RAMS Co-Investigators, Barton A, Verstappen SMM.

Arthritis Res Ther. 2018 Jul 13;20(1):147. doi: 10.1186/s13075-018-1645-5.

19.

Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.

Subesinghe S, Rutherford AI, Byng-Maddick R, Hyrich KL, Galloway JB.

Rheumatology (Oxford). 2018 Dec 1;57(12):2096-2100. doi: 10.1093/rheumatology/key198.

PMID:
29986108
20.

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, Isaacs JD, Hyrich KL; BSRBR-RA Contributors Group.

Ann Rheum Dis. 2018 Oct;77(10):1405-1412. doi: 10.1136/annrheumdis-2018-213378. Epub 2018 Jul 6.

21.

Long-Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition.

Shoop-Worrall SJW, Verstappen SMM, McDonagh JE, Baildam E, Chieng A, Davidson J, Foster H, Ioannou Y, McErlane F, Wedderburn LR, Thomson W, Hyrich KL.

Arthritis Rheumatol. 2018 Sep;70(9):1519-1529. doi: 10.1002/art.40519. Epub 2018 Jul 22.

22.

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB.

Ann Rheum Dis. 2018 Jun;77(6):905-910. doi: 10.1136/annrheumdis-2017-212825. Epub 2018 Mar 28.

PMID:
29592917
23.

Long-term persistence with rituximab in patients with rheumatoid arthritis.

Oldroyd AGS, Symmons DPM, Sergeant JC, Kearsley-Fleet L, Watson K, Lunt M, Hyrich KL; BSRBR-RA Contributors Group.

Rheumatology (Oxford). 2018 Jun 1;57(6):1089-1096. doi: 10.1093/rheumatology/key036.

24.

Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB.

Rheumatology (Oxford). 2018 Jun 1;57(6):997-1001. doi: 10.1093/rheumatology/key023.

PMID:
29529307
25.

Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.

Fagerli KM, Kearsley-Fleet L, Watson KD, Packham J, Contributors Group BR, Symmons DPM, Hyrich KL.

RMD Open. 2018 Jan 7;4(1):e000596. doi: 10.1136/rmdopen-2017-000596. eCollection 2018.

26.

The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register.

Matcham F, Davies R, Hotopf M, Hyrich KL, Norton S, Steer S, Galloway J.

Rheumatology (Oxford). 2018 May 1;57(5):835-843. doi: 10.1093/rheumatology/kex528.

PMID:
29447376
27.

Assessing the safety of new drugs during pregnancy.

Hyrich KL.

Br J Dermatol. 2018 Jan;178(1):18-19. doi: 10.1111/bjd.16057. No abstract available.

PMID:
29357613
28.

2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis.

Radner H, Chatzidionysiou K, Nikiphorou E, Gossec L, Hyrich KL, Zabalan C, van Eijk-Hustings Y, Williamson PR, Balanescu A, Burmester GR, Carmona L, Dougados M, Finckh A, Haugeberg G, Hetland ML, Oliver S, Porter D, Raza K, Ryan P, Santos MJ, van der Helm-van Mil A, van Riel P, von Krause G, Zavada J, Dixon WG, Askling J.

Ann Rheum Dis. 2018 Apr;77(4):476-479. doi: 10.1136/annrheumdis-2017-212256. Epub 2018 Jan 4.

PMID:
29301783
29.

Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS).

McErlane F, Carrasco R, Kearsley-Fleet L, Baildam EM, Wedderburn LR, Foster HE, Ioannou Y, Chieng SEA, Davidson JE, Thomson W, Hyrich KL.

Semin Arthritis Rheum. 2018 Aug;48(1):53-60. doi: 10.1016/j.semarthrit.2017.11.002. Epub 2017 Nov 7.

30.

Patterns of pain over time among children with juvenile idiopathic arthritis.

Rashid A, Cordingley L, Carrasco R, Foster HE, Baildam EM, Chieng A, Davidson JE, Wedderburn LR, Ioannou Y, McErlane F, Verstappen SMM, Hyrich KL, Thomson W.

Arch Dis Child. 2018 May;103(5):437-443. doi: 10.1136/archdischild-2017-313337. Epub 2017 Nov 25.

31.

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Silva-Fernández L, De Cock D, Lunt M, Low AS, Watson KD; BSRBR-RA Contributors Group, Symmons DPM, Hyrich KL.

Rheumatology (Oxford). 2018 Sep 1;57(9):1533-1540. doi: 10.1093/rheumatology/kex304.

32.

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.

Druce KL, Iqbal K, Watson KD, Symmons DPM, Hyrich KL, Kelly C.

RMD Open. 2017 Jul 13;3(1):e000473. doi: 10.1136/rmdopen-2017-000473. eCollection 2017.

33.

How common is remission in juvenile idiopathic arthritis: A systematic review.

Shoop-Worrall SJW, Kearsley-Fleet L, Thomson W, Verstappen SMM, Hyrich KL.

Semin Arthritis Rheum. 2017 Dec;47(3):331-337. doi: 10.1016/j.semarthrit.2017.05.007. Epub 2017 May 20. Review.

34.

Biologics registers in RA: methodological aspects, current role and future applications.

Nikiphorou E, Buch MH, Hyrich KL.

Nat Rev Rheumatol. 2017 Aug;13(8):503-510. doi: 10.1038/nrrheum.2017.81. Epub 2017 Jun 1. Review.

35.

How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition.

Shoop-Worrall SJW, Verstappen SMM, Baildam E, Chieng A, Davidson J, Foster H, Ioannou Y, McErlane F, Wedderburn LR, Thomson W, Hyrich KL.

Ann Rheum Dis. 2017 Aug;76(8):1381-1388. doi: 10.1136/annrheumdis-2016-210511. Epub 2017 Apr 7. Erratum in: Ann Rheum Dis. 2017 Oct;76(10):1783-1784.

36.

Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab.

De Cock D, Birmingham L, Watson KD, Kearsley-Fleet L; BSRBR Control Centre Consortium, Symmons DP, Hyrich KL.

Rheumatology (Oxford). 2017 Apr 1;56(4):661-663. doi: 10.1093/rheumatology/kew493. No abstract available.

PMID:
28137762
37.

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, Lunt M, Watson K; BSRBR-RA*; BSRBR-RA Control Centre Consortium*, Symmons DP, Hyrich KL.

RMD Open. 2017 Jan 17;3(1):e000314. doi: 10.1136/rmdopen-2016-000314. eCollection 2017. Erratum in: RMD Open. 2017 Feb 23;3(1):e000314corr1.

38.

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.

Low AS, Symmons DP, Lunt M, Mercer LK, Gale CP, Watson KD, Dixon WG, Hyrich KL; British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and the BSRBR Control Centre Consortium.

Ann Rheum Dis. 2017 Apr;76(4):654-660. doi: 10.1136/annrheumdis-2016-209784. Epub 2017 Jan 10.

39.

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register.

Saad AA, Ashcroft DM, Watson KD, Symmons DPM, Noyce PR, Hyrich KL; BSRBR.

Rheumatology (Oxford). 2017 Apr 1;56(4):672-673. doi: 10.1093/rheumatology/kew454. No abstract available.

40.

Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al.

Mercer LK, Galloway JB, Lunt M, Davies R, Low AA, Dixon WG, Watson KD, Symmons DP, Hyrich KL.

Ann Rheum Dis. 2017 Feb;76(2):e4. doi: 10.1136/annrheumdis-2016-210631. Epub 2016 Dec 1. No abstract available.

PMID:
27934677
41.

Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.

Davies R, Gaynor D, Hyrich KL, Pain CE.

Semin Arthritis Rheum. 2017 Apr;46(5):584-593. doi: 10.1016/j.semarthrit.2016.10.008. Epub 2016 Nov 1. Review.

PMID:
27914689
42.

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.

Kihara M, Davies R, Kearsley-Fleet L, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Clin Rheumatol. 2017 Feb;36(2):241-250. doi: 10.1007/s10067-016-3485-5. Epub 2016 Dec 2.

43.

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis.

Kearsley-Fleet L, McErlane F, Foster HE, Lunt M, Watson KD, Symmons DP, Hyrich KL.

RMD Open. 2016 Oct 7;2(2):e000273. eCollection 2016.

44.

Mortality rates are increased in patients with systemic juvenile idiopathic arthritis.

Davies R, Southwood T, Kearsley-Fleet L, Lunt M, Baildam E, Beresford MW, Foster HE, Douglas S, Thomson W, De Cock D; BCRD Study Group; BSPAR-ETN Study Group, Hyrich KL.

Arch Dis Child. 2017 Feb;102(2):206-207. doi: 10.1136/archdischild-2016-311571. Epub 2016 Oct 31. No abstract available.

PMID:
27799155
45.

Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature.

Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, van Eijk-Hustings Y, Dixon WG, Hyrich KL, Askling J, Gossec L.

Arthritis Res Ther. 2016 Oct 28;18(1):251. Review.

46.

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.

Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A.

Rheumatology (Oxford). 2016 Nov;55(11):2050-2055. Epub 2016 Aug 25.

47.

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.

Silva-Fernández L, Lunt M, Kearsley-Fleet L, Watson KD, Dixon WG, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium.

Rheumatology (Oxford). 2016 Nov;55(11):2033-2039. Epub 2016 Aug 22.

48.

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, Watson KD; BSRBR Control Centre Consortium, Symmons DP, Hyrich KL.

Ann Rheum Dis. 2017 Mar;76(3):497-503. doi: 10.1136/annrheumdis-2016-209389. Epub 2016 Aug 8.

49.

Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).

Davies R, Carrasco R, Foster HE, Baildam EM, Chieng SEA, Davidson JE, Ioannou Y, Wedderburn LR, Thomson W, Hyrich KL.

Semin Arthritis Rheum. 2016 Oct;46(2):190-195. doi: 10.1016/j.semarthrit.2016.06.001. Epub 2016 Jun 8.

50.

Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis.

Olsen CM, Hyrich KL, Knight LL, Green AC.

Melanoma Res. 2016 Oct;26(5):517-23. doi: 10.1097/CMR.0000000000000284. Review.

PMID:
27391143

Supplemental Content

Loading ...
Support Center